Cargando…
Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Turkish League Against Rheumatism
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791548/ https://www.ncbi.nlm.nih.gov/pubmed/36589603 http://dx.doi.org/10.46497/ArchRheumatol.2022.9108 |
_version_ | 1784859430207094784 |
---|---|
author | Da Silva, Lila Morena Bueno Rathore, Upendra Agarwal, Vikas Gupta, Latika Shinjo, Samuel Katsuyuki |
author_facet | Da Silva, Lila Morena Bueno Rathore, Upendra Agarwal, Vikas Gupta, Latika Shinjo, Samuel Katsuyuki |
author_sort | Da Silva, Lila Morena Bueno |
collection | PubMed |
description | OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was conducted at two tertiary rheumatology centers (one in Brazil and one in India) between January 2000 to January 2020 included a total of 115 patients with ASSD (21 males, 94 females; mean age; at disease diagnosis at 40.3; range, 18 to 80 years). Demographic, clinical and laboratory data of the patients were recorded. Clinical involvement was evaluated. RESULTS: Of the patients, 81 were Brazilians and 34 were of Indian origin. The Indian group exhibited a greater delay in diagnosis after the onset of symptoms compared to Brazilian patients (12 vs. 6 months, respectively; p=0.026). Brazilian patients exhibited a significantly higher prevalence of joint and lung involvement, mechanic’s hands, and Raynaud’s phenomenon. Anti-Jo-1 was the most common autoantibodies in both groups. Systemic arterial hypertension, followed by diabetes mellitus were the most prevalent comorbidities. Concerning previously used drugs, the Indian patients had a larger group of patients treated with antimalarials, whereas the Brazilian group used more azathioprine and intravenous immunoglobulin. A higher proportion of Indian patients was treated with one immunosuppressive drug (70.6%), while the Brazilian group were often treated using two immunosuppressive drugs (33%). Comparison between the severity and prognosis showed that Brazilian group had a higher number of relapses, and during follow-up, the global mortality rates were similar in both groups (6.2% for Brazilian vs. 8.8% for Indian). CONCLUSION: Brazilian and Indian patients with ASSD have comparable epidemiological characteristics such as age at the time of disease diagnosis, and sex distribution, and autoantibodies. Diagnostic delay is seen in Indian patients, and Brazilians exhibit a higher prevalence of joint and lung involvement, mechanic’s hands, Raynaud’s phenomenon with a higher number of relapses, although the mortality rate seems to be similar in both groups. |
format | Online Article Text |
id | pubmed-9791548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Turkish League Against Rheumatism |
record_format | MEDLINE/PubMed |
spelling | pubmed-97915482022-12-30 Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study Da Silva, Lila Morena Bueno Rathore, Upendra Agarwal, Vikas Gupta, Latika Shinjo, Samuel Katsuyuki Arch Rheumatol Original Article OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was conducted at two tertiary rheumatology centers (one in Brazil and one in India) between January 2000 to January 2020 included a total of 115 patients with ASSD (21 males, 94 females; mean age; at disease diagnosis at 40.3; range, 18 to 80 years). Demographic, clinical and laboratory data of the patients were recorded. Clinical involvement was evaluated. RESULTS: Of the patients, 81 were Brazilians and 34 were of Indian origin. The Indian group exhibited a greater delay in diagnosis after the onset of symptoms compared to Brazilian patients (12 vs. 6 months, respectively; p=0.026). Brazilian patients exhibited a significantly higher prevalence of joint and lung involvement, mechanic’s hands, and Raynaud’s phenomenon. Anti-Jo-1 was the most common autoantibodies in both groups. Systemic arterial hypertension, followed by diabetes mellitus were the most prevalent comorbidities. Concerning previously used drugs, the Indian patients had a larger group of patients treated with antimalarials, whereas the Brazilian group used more azathioprine and intravenous immunoglobulin. A higher proportion of Indian patients was treated with one immunosuppressive drug (70.6%), while the Brazilian group were often treated using two immunosuppressive drugs (33%). Comparison between the severity and prognosis showed that Brazilian group had a higher number of relapses, and during follow-up, the global mortality rates were similar in both groups (6.2% for Brazilian vs. 8.8% for Indian). CONCLUSION: Brazilian and Indian patients with ASSD have comparable epidemiological characteristics such as age at the time of disease diagnosis, and sex distribution, and autoantibodies. Diagnostic delay is seen in Indian patients, and Brazilians exhibit a higher prevalence of joint and lung involvement, mechanic’s hands, Raynaud’s phenomenon with a higher number of relapses, although the mortality rate seems to be similar in both groups. Turkish League Against Rheumatism 2022-03-03 /pmc/articles/PMC9791548/ /pubmed/36589603 http://dx.doi.org/10.46497/ArchRheumatol.2022.9108 Text en Copyright © 2022, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Article Da Silva, Lila Morena Bueno Rathore, Upendra Agarwal, Vikas Gupta, Latika Shinjo, Samuel Katsuyuki Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title | Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title_full | Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title_fullStr | Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title_full_unstemmed | Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title_short | Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study |
title_sort | demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: an international, two-center cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791548/ https://www.ncbi.nlm.nih.gov/pubmed/36589603 http://dx.doi.org/10.46497/ArchRheumatol.2022.9108 |
work_keys_str_mv | AT dasilvalilamorenabueno demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy AT rathoreupendra demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy AT agarwalvikas demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy AT guptalatika demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy AT shinjosamuelkatsuyuki demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy |